Gyre Therapeutics, Inc.GYRENASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank92
5Y CAGR+36.2%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+36.2%/yr
Long-term compound
Percentile
P92
Near historical high
vs 5Y Ago
4.7x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 55.33% |
| Q3 2025 | -1.88% |
| Q2 2025 | 26.76% |
| Q1 2025 | -29.23% |
| Q4 2024 | 27.38% |
| Q3 2024 | -1.77% |
| Q2 2024 | 11.91% |
| Q1 2024 | -39.89% |
| Q4 2023 | 75.80% |
| Q3 2023 | -23.47% |
| Q2 2023 | 35.87% |
| Q1 2023 | -34.90% |
| Q4 2022 | -1.82% |
| Q3 2022 | 490.41% |
| Q2 2022 | -73.86% |
| Q1 2022 | 253.22% |
| Q4 2021 | -14.48% |
| Q3 2021 | 7.77% |
| Q2 2021 | -16.52% |
| Q1 2021 | 26.30% |
| Q4 2020 | 11.79% |
| Q3 2020 | -12.31% |
| Q2 2020 | 18.42% |
| Q1 2020 | 16.80% |
| Q4 2019 | -3.30% |
| Q3 2019 | -0.06% |
| Q2 2019 | -11.31% |
| Q1 2019 | 7.02% |
| Q4 2018 | 24.37% |
| Q3 2018 | -14.11% |
| Q2 2018 | 10.67% |
| Q1 2018 | 12.68% |
| Q4 2017 | 8.16% |
| Q3 2017 | -9.91% |
| Q2 2017 | 11.47% |
| Q1 2017 | 9.27% |
| Q4 2016 | -10.14% |
| Q3 2016 | 6.73% |
| Q2 2016 | -5.14% |
| Q1 2016 | -20.88% |